Skip to main content
Contact Us
Subscribe
E-Edition
39°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ainos, Inc. - warrants
(NQ:
AIMDW
)
0.1300
-0.0009 (-0.69%)
Streaming Delayed Price
Updated: 10:46 AM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ainos, Inc. - warrants
< Previous
1
2
3
Next >
Ainos Reports Full Year 2023 Financial Results
March 08, 2024
Via
ACCESSWIRE
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
February 05, 2024
Via
ACCESSWIRE
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
February 01, 2024
Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Ainos Announces $1.75 Million Follow-On Funding
January 24, 2024
Via
ACCESSWIRE
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 02, 2024
Via
ACCESSWIRE
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
November 28, 2023
Via
ACCESSWIRE
Ainos Reports Third Quarter 2023 Financial Results
November 09, 2023
Via
ACCESSWIRE
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
September 25, 2023
Via
ACCESSWIRE
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
December 26, 2023
Via
ACCESSWIRE
Ainos, Inc. Announces Stock Consolidation
December 12, 2023
Via
ACCESSWIRE
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
November 21, 2023
Via
ACCESSWIRE
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
September 18, 2023
Via
ACCESSWIRE
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
September 05, 2023
Via
ACCESSWIRE
Ainos Reports Second Quarter 2023 Financial Results
August 11, 2023
Via
ACCESSWIRE
Ainos Celebrates First Listing Anniversary on Nasdaq
August 10, 2023
Via
ACCESSWIRE
Ainos Issues Mid-Year Business Update Letter to Shareholders
June 27, 2023
Via
ACCESSWIRE
Ainos Provides Insights Into Its AI Nose Technology
June 20, 2023
Via
ACCESSWIRE
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
August 09, 2023
Via
ACCESSWIRE
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target
June 14, 2023
Via
ACCESSWIRE
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
June 07, 2023
Via
ACCESSWIRE
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
May 30, 2023
Via
ACCESSWIRE
Ainos Appoints Amanda Sung as New Chief Financial Officer
May 17, 2023
Via
ACCESSWIRE
Ainos Reports First Quarter 2023 Financial Results
May 12, 2023
Via
ACCESSWIRE
Ainos Reports Fourth Quarter and Full Year 2022 Financial Results
March 31, 2023
Via
ACCESSWIRE
Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan
March 21, 2023
Via
ACCESSWIRE
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug
January 23, 2023
Via
ACCESSWIRE
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
March 14, 2023
Via
ACCESSWIRE
Ainos Announces US$3 Million Convertible Notes Private Placement
March 13, 2023
Via
ACCESSWIRE
Ainos Issues 2023 Shareholder Letter
January 17, 2023
Via
ACCESSWIRE
Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization
October 31, 2022
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
